Overview |
bsm-54677R |
EWSR1/EWS Monoclonal Antibody |
WB, IHC-P, IF(ICC), IHC |
Human, Mouse, Rat |
Specifications |
Unconjugated |
Rabbit |
Synthetic Peptide within N terminal human EWSR1/EWS. |
Monoclonal |
4G8 |
IgG |
1ug/ul |
Purified by Protein A. |
Aqueous buffered solution containing 1xTBS (pH7.4), 1%BSA, 40%Glycerol and 0.05% Sodium Azide. |
Store at -20°C for 12 months. |
Target |
2130 |
Q01844 |
Cytoplasm, Nucleus, Plasma membrane |
bK984G1.4 antibody, bK984G1.4 Ewing sarcoma breakpoint region 1 protein antibody, Ewing sarcoma breakpoint region 1 antibody, Ewing sarcoma breakpoint region 1 protein antibody, Ewings sarcoma EWS Fli1 type 1 oncogene antibody, EWS antibody, EWS oncogene antibody, EWS RNA binding protein 1 antibody, EWS_HUMAN antibody, EWSR 1 antibody, Ewsr1 antibody, EWSR1 protein antibody, RNA binding protein EWS antibody, RNA-binding protein EWS antibody |
EWS is a nuclear RNA-binding protein. As a result of chromosome translocation, the EWS gene is fused to a variety of transcription factors, including ATF-1 in human neoplasias. In the Ewing family of tumors, the N-terminal domain of EWS is fused to the DNA-binding domain of various ETS transcription factors, including Fli-1, Erg, ETV1, E1AF and FEV. The EWS/Fli-1 chimeric protein acts as a more potent transcriptional activator than Fli-1 and can promote cell transformation. Two functional regions have been identified in EWS; an amino-terminal region (domain A), that has little transactivation activity but transforms efficiently when fused to Fli-1, and a distal region (domain B), which shows transactivation activity but transforms less efficiently when fused to Fli-1. |
Application Dilution |
WB |
1:300-5000 |
IHC-P |
1:200-400 |
IF(ICC) |
1:50-200 |
IHC |
|